Company logo

KRBP - Kiromic BioPharma, Inc.

NASDAQ -> Healthcare -> Biotechnology
Houston, United States

KRBP price evolution
KRBP
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Current assets
Cash $3.07 $7.34 $10.15 $0.47
Short term investments
Net receivables
Inventory $0.02
Total current assets $3.95 $7.85 $10.74 $1.54
Long term investments
Property, plant & equipment $2.47 $2.28 $2.07 $1.61
Goodwill & intangible assets
Total noncurrent assets $2.49 $2.3 $2.09 $1.64
Total investments
Total assets $6.44 $10.15 $12.83 $3.18
Current liabilities
Accounts payable $1.12 $1.2 $0.67 $1.67
Deferred revenue
Short long term debt $0.09 $0.23 $0.47 $0.11
Total current liabilities $1.57 $1.7 $1.47 $2.25
Long term debt
Total noncurrent liabilities
Total debt $0.09 $0.23 $0.47 $0.11
Total liabilities $1.57 $1.7 $1.47 $2.25
Shareholders' equity
Retained earnings -$50.46 -$45.48 -$41.63 -$38.06
Other shareholder equity
Total shareholder equity $4.87 $8.45 $11.36 $0.93
(in millions $) 31 Dec 2020 31 Dec 2019
Current assets
Cash $10.15 $1.93
Short term investments
Net receivables
Inventory $0.02
Total current assets $10.74 $2.04
Long term investments
Property, plant & equipment $2.07 $0.59
Goodwill & intangible assets
Total noncurrent assets $2.09 $0.61
Total investments
Total assets $12.83 $2.65
Current liabilities
Accounts payable $0.67 $0.45
Deferred revenue
Short long term debt $0.47
Total current liabilities $1.47 $0.67
Long term debt
Total noncurrent liabilities
Total debt $0.47
Total liabilities $1.47 $0.67
Shareholders' equity
Retained earnings -$41.63 -$22.43
Other shareholder equity
Total shareholder equity $11.36 $1.98
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $2.66 $1.89 $1.53 $1.23
Selling, general & administrative $2.31 $2.07 $2.03 $1.19
Total operating expenses $4.97 $3.96 $3.56 $2.42
Operating income -$4.97 -$3.96 -$3.56 -$2.42
Income from continuing operations
EBIT -$4.97 -$3.85 -$3.56 -$2.42
Income tax expense
Interest expense $0 $0 $0
Net income
Net income -$4.97 -$3.85 -$3.56 -$2.42
Income (for common shares) -$4.97 -$3.85 -$3.56 -$2.42
(in millions $) 31 Dec 2020 31 Dec 2019
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $5.05 $1.2
Selling, general & administrative $14.14 $2.5
Total operating expenses $19.2 $3.68
Operating income -$19.2 -$3.68
Income from continuing operations
EBIT -$19.2 -$3.71
Income tax expense
Interest expense $0 $0.02
Net income
Net income -$19.2 -$3.73
Income (for common shares) -$19.2 -$3.73
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Net income -$4.97 -$3.85 -$3.56 -$2.42
Operating activities
Depreciation $0.11 $0.1 $0.08 $0.05
Business acquisitions & disposals
Stock-based compensation $1.27 $0.95 $1.67 $1.25
Total cash flows from operations -$3.71 -$2.64 -$2.57 -$0.95
Investing activities
Capital expenditures -$0.55 -$0.04 -$0.44 -$0.25
Investments
Total cash flows from investing -$0.55 -$0.04 -$0.44 -$0.25
Financing activities
Dividends paid
Sale and purchase of stock $0.13 $15
Net borrowings -$0.14 -$0.13 $0.36 -$0.01
Total cash flows from financing -$0.01 -$0.13 $12.7 -$0.01
Effect of exchange rate
Change in cash and equivalents -$4.26 -$2.82 $9.68 -$1.21
(in millions $) 31 Dec 2020 31 Dec 2019
Net income -$19.2 -$3.73
Operating activities
Depreciation $0.2 $0.09
Business acquisitions & disposals
Stock-based compensation $13.25 $0.52
Total cash flows from operations -$6.13 -$2.91
Investing activities
Capital expenditures -$1.46 -$0.3
Investments
Total cash flows from investing -$1.46 -$0.3
Financing activities
Dividends paid
Sale and purchase of stock $15 $0.01
Net borrowings $0.47 $0.25
Total cash flows from financing $15.81 $4.76
Effect of exchange rate
Change in cash and equivalents $8.22 $1.54
Fundamentals
Market cap $35.51M
Enterprise value $32.53M
Shares outstanding 15.44M
Revenue $0.00
EBITDA -$14.47M
EBIT -$14.80M
Net Income -$14.81M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -2.40
EV/Sales N/A
EV/EBITDA -2.25
EV/EBIT -2.20
P/S ratio N/A
P/B ratio 7.29
Book/Share 0.32
Cash/Share 0.20
EPS -$0.96
ROA -181.70%
ROE -231.25%
Debt/Equity 0.13
Net debt/EBITDA 0.10
Current ratio 2.52
Quick ratio 2.52